Key result
NOACs were successfully included in the 21st WHO Model List of Essential Medicines based on evidence showing non-inferiority or superiority to warfarin for stroke and systemic embolism prevention.
Why the study?
Major practice guidelines recommend NOACs over VKAs for initial AF stroke prevention, motivating documentation of the evidence and process for including NOACs in the WHO Model List of Essential Medicines.
Do NOACs reduce stroke, systemic embolism, and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation?
Do NOACs reduce stroke, systemic embolism, and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation?
The inclusion of NOACs in the WHO Essential Medicines List is a critical step for global cardiovascular health, particularly in low- and middle-income countries.
No takes yet. Share an insight, caveat, or question.
Inclusion may improve NOAC access in LMICs; leaves open real-world effectiveness and implementation questions.
Zaidel et al. (2020) conducted a review in Non-valvular atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin was evaluated on Stroke and systemic embolism. NOACs were successfully included in the 21st WHO Model List of Essential Medicines based on evidence showing non-inferiority or superiority to warfarin for stroke and systemic embolism prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: